Jie Ni

List of Publications by Year in Descending Order

40 papers	1,862 citations	23 h-index	43 g-index
49 ext. papers	2,353 ext. citations	6.8 avg, IF	4.94 L-index

#	Paper	IF	Citations
40	THOC2 and THOC5 Regulate Stemness and Radioresistance in Triple-Negative Breast Cancer. *Advanced Science*, **2021**, 8, e2102658	13.6	2
39	Endoplasmic Reticulum Stress and Tumor Microenvironment in Bladder Cancer: The Missing Link. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 683940	5.7	4
38	Activation of the eIF2α/ATF4 axis drives triple-negative breast cancer radioresistance by promoting glutathione biosynthesis. *Redox Biology*, **2021**, 43, 101993	11.3	1
37	Triple-negative breast cancer therapeutic resistance: Where is the Achilles'Sheel?. *Cancer Letters*, **2021**, 497, 100-111	9.9	30
36	Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance. *Journal of the National Cancer Center*, **2021**, 1, 75-75		1
35	CD44 variant 6 is associated with prostate cancer growth and chemo-/radiotherapy response in vivo. *Experimental Cell Research*, **2020**, 388, 111850	4.2	3
34	Quality Assessment and Comparison of Plasma-Derived Extracellular Vesicles Separated by Three Commercial Kits for Prostate Cancer Diagnosis. *International Journal of Nanomedicine*, **2020**, 15, 10241-10256	7.3	4
33	Extracellular vesicles: the next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis. *Theranostics*, **2020**, 10, 2309-2326	12.1	70
32	Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer. *Critical Reviews in Oncology/Hematology*, **2020**, 145, 102860	7	47
31	Exosomes and breast cancer drug resistance. *Cell Death and Disease*, **2020**, 11, 987	9.8	35
30	A Clinician's Guide to Cancer-Derived Exosomes: Immune Interactions and Therapeutic Implications. *Frontiers in Immunology*, **2020**, 11, 1612	8.4	13
29	Cancer stem cells in prostate cancer radioresistance. *Cancer Letters*, **2019**, 465, 94-104	9.9	27
28	Exosomes in Cancer Radioresistance. *Frontiers in Oncology*, **2019**, 9, 869	5.3	33
27	In Vivo 3D MRI Measurement of Tumour Volume in an Orthotopic Mouse Model of Prostate Cancer. *Cancer Control*, **2019**, 26, 1073274819846590	2.2	5
26	Liquid biopsy in ovarian cancer: recent advances in circulating extracellular vesicle detection for early diagnosis and monitoring progression. *Theranostics*, **2019**, 9, 4130-4140	12.1	35
25	CHTOP in Chemoresistant Epithelial Ovarian Cancer: A Novel and Potential Therapeutic Target. *Frontiers in Oncology*, **2019**, 9, 557	5.3	1
24	Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression. *BMC Cancer*, **2019**, 19, 618	4.8	85

23	Cancer stem cell in breast cancer therapeutic resistance. *Cancer Treatment Reviews*, **2018**, 69, 152-163	14.4	108
22	Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo. *BMC Cancer*, **2018**, 18, 1092	4.8	19
21	Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach. *Scientific Reports*, **2017**, 7, 41834	4.9	35
20	Enhanced osteointegration of tantalum-modified titanium implants with micro/nano-topography. *RSC Advances*, **2017**, 7, 46472-46479	3.7	8
19	Urinary biomarkers in prostate cancer detection and monitoring progression. *Critical Reviews in Oncology/Hematology*, **2017**, 118, 15-26	7	49
18	Targeting MicroRNAs in Prostate Cancer Radiotherapy. *Theranostics*, **2017**, 7, 3243-3259	12.1	48
17	Monitoring Prostate Tumor Growth in an Orthotopic Mouse Model Using Three-Dimensional Ultrasound Imaging Technique. *Translational Oncology*, **2016**, 9, 41-45	4.9	14
16	Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy. *Oncotarget*, **2016**, 7, 74269-74285	3.3	21
15	Cancer stem cells and signaling pathways in radioresistance. *Oncotarget*, **2016**, 7, 11002-17	3.3	69
14	Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer. *Oncotarget*, **2016**, 7, 55771-55788	3.3	74
13	Clinical Evaluation and Patient Satisfaction of Single Zirconia-Based and High-Noble Alloy Porcelain-Fused-to-Metal Crowns in the Esthetic Area: A Retrospective Cohort Study. *Journal of Prosthodontics*, **2016**, 25, 526-530	3.9	9
12	Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy. *Expert Review of Proteomics*, **2016**, 13, 905-915	4.2	5
11	Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. *Critical Reviews in Oncology/Hematology*, **2015**, 96, 507-17	7	121
10	PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. *Cell Death and Disease*, **2014**, 5, e1437	9.8	205
9	CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. *Prostate*, **2014**, 74, 602-17	4.2	97
8	Cancer stem cells in prostate cancer chemoresistance. *Current Cancer Drug Targets*, **2014**, 14, 225-40	2.8	41
7	Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. *International Journal of Biochemistry and Cell Biology*, **2013**, 45, 2736-48	5.6	122
6	Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. *Cell Death and Disease*, **2013**, 4, e875	9.8	252

5	The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression. *Cancer and Metastasis Reviews*, **2013**, 32, 535-51	9.6	60
4	Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro. *Cancer Letters*, **2013**, 329, 17-26	9.9	22
3	The CD44 Isoforms in Prostate Cancer Metastasis and Progression **2013**, 1, 3-14		3
2	Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells. *PLoS ONE*, **2013**, 8, e74253	3.7	30
1	Role of the EpCAM (CD326) in prostate cancer metastasis and progression. *Cancer and Metastasis Reviews*, **2012**, 31, 779-91	9.6	53